Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Exelixis
Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Official title: A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-08-18
Completion Date
2028-02
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
XB371
Intravenous (IV) infusion.
Locations (9)
Exelixis Clinical Site #5
Rogers, Arkansas, United States
Exelixis Clinical Site #9
Los Angeles, California, United States
Exelixis Clinical Site #6
Washington D.C., District of Columbia, United States
Exelixis Clinical Site #4
Orlando, Florida, United States
Exelixis Clinical Site #3
Grand Rapids, Michigan, United States
Exelixis Clinical Site #7
New Brunswick, New Jersey, United States
Exelixis Clinical Site #2
Huntersville, North Carolina, United States
Exelixis Clinical Site #8
Houston, Texas, United States
Exelixis Clinical Site #1
San Antonio, Texas, United States